Effects of β 2 -receptor stimulation by indacaterol in chronic heart failure treated with selective or non-selective β-blockers: a randomized trial
SCIENTIFIC REPORTS(2020)
Abstract
Alveolar β 2 -receptor blockade worsens lung diffusion in heart failure (HF). This effect could be mitigated by stimulating alveolar β 2 -receptors. We investigated the safety and the effects of indacaterol on lung diffusion, lung mechanics, sleep respiratory behavior, cardiac rhythm, welfare, and exercise performance in HF patients treated with a selective (bisoprolol) or a non-selective (carvedilol) β-blocker. Study procedures were performed before and after indacaterol and placebo treatments according to a cross-over, randomized, double-blind protocol in forty-four patients (27 on bisoprolol and 17 on carvedilol). No differences between indacaterol and placebo were observed in the whole population except for a significantly higher VE/VCO 2 slope and lower maximal P ET CO 2 during exercise with indacaterol, entirely due to the difference in the bisoprolol group (VE/VCO 2 31.8 ± 5.9 vs. 28.5 ± 5.6, p < 0.0001 and maximal P ET CO 2 36.7 ± 5.5 vs. 37.7 ± 5.8 mmHg, p < 0.02 with indacaterol and placebo, respectively). In carvedilol, indacaterol was associated with a higher peak heart rate (119 ± 34 vs. 113 ± 30 bpm, with indacaterol and placebo) and a lower prevalence of hypopnea during sleep (3.8 [0.0;6.3] vs. 5.8 [2.9;10.5] events/hour, with indacaterol and placebo). Inhaled indacaterol is well tolerated in HF patients, it does not influence lung diffusion, and, in bisoprolol, it increases ventilation response to exercise.
MoreTranslated text
Key words
Cardiology,Drug development,Science,Humanities and Social Sciences,multidisciplinary
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined